---
company: HUMANA INC
ticker: HUM
form: 8-K
filed: 2026-11-06
accepted: 2026-11-06T11:09:28+00:00
accession: 0000049071-26-000064
source: https://www.sec.gov/Archives/edgar/data/49071/000004907126000064/
quarterly_report: https://www.sec.gov/Archives/edgar/data/49071/000004907126000066/
---

# Humana (HUM) Q3 2026 earnings

## Header

- Company: Humana Inc
- Reported: 2026-11-06 06:09 BMO ET
- Source: 8-K only — accession 0000049071-26-000064, Item 2.02 + Exhibit 99.1
- Verdict: Raises full year Adjusted EPS guidance to at least $9.50 as 3Q26 GAAP EPS of $1.33 and YTD 2026 GAAP EPS of $16.84 beat the prior quarter's YTD of $15.55.

## Headline numbers

| Metric | Actual | YoY | QoQ | 8-K location |
|---|---|---|---|---|
| EPS (GAAP) | $1.33 | +0.71 | -4.40 | Ex. 99.1, income statement |
| EPS (adjusted) | -$0.70 | -$3.94 | -$8.31 | Ex. 99.1, income statement |
| Net income | $162M | -$33M | -$532M | Ex. 99.1, income statement |
| Adj. EBITDA | $1,964M | -$655M | -$12M | Ex. 99.1, income statement |
| Adj. EBITDA margin | 7.4% | -1.1 pp | 0.0 pp | Ex. 99.1, income statement |

## Revenue breakdown

| Segment | Actual | YoY | Share of revenue | Note |
|---|---:|---:|---:|---|
| Insurance | $31,189M | +1.2% | 75.6% | Benefit ratio 91.1% |
| CenterWell | $5,879M | +0.9% | 14.2% | Operating cost ratio 93.9% |
| Consolidated | $41,155M | +26.3% | 100% | Benefit ratio 93.9% |

## Margins and costs

- Gross margin: 4.1% (prior 6.1%, change -2.0 pp)
- Operating expenses: $4,598M (+12.8% YoY)
- One-offs in the quarter: Put/call valuation adjustments ($1.2B noncash reversal); Initial option liability associated with BlackRock JV (expected in Q4)
- Effective tax rate: 18.5% (prior-year 36.9%, year-to-date 24.3%)
- Non-GAAP bridge: Adds back amortization, put/call valuation adjustments, value creation initiatives, impairment charges, and cumulative net tax impact to GAAP results.

## KPIs

| Metric | Actual | Prior quarter | Prior year | Change |
|---|---:|---:|---:|---:|
| Operating cash flows | $5,383M | $3,220M | $2,573M | +67.2% |
| Days in Claims Payable (DCP) | 33.2 | 33.2 | 33.2 | 0.0 |
| Debt-to-total capitalization | 40.9% | 40.9% | 40.3% | +0.6 pp |

## Guidance

| Metric | Guide | Prior guide | Change |
|---|---|---|---:|
| Adjusted EPS | at least $9.50 | at least $9.00 | +0.50 |
| GAAP EPS | at least $15.09 | at least $6.52 | +8.57 |
| Total Revenues | at least $160B | at least $160B | 0.00 |
| Insurance segment benefit ratio | 92.75% +/- 25 bps | 92.75% +/- 25 bps | 0.00 |
| Consolidated operating cost ratio | 10.0% +/- 25 bps | 10.0% +/- 25 bps | 0.00 |

## What drove it

- Revenue story: Consolidated revenues grew 26.3% YoY to $41.16B, driven by premiums ($38.70B, +25.9%) and services ($2.13B, +33.1%).
- EPS story: GAAP EPS fell YoY due to a $0.01 adjustment to the weighted-average share count used for Adjusted EPS, while the Adjusted loss per share reflects the reversal of a put liability and the initial option liability from the new JV.
- One-off check: Put/call valuation adjustments ($1.2B noncash reversal) and initial option liability from BlackRock JV (expected in Q4).

## The good

- Operating cash flows of $5.38B (+67% YoY)
- Insurance segment benefit ratio of 91.1% (favorable to guidance of slightly above 94%)

## The bad

- Consolidated operating loss of $303M (vs. $251M income YoY)
- Adjusted EBITDA margin of 7.4% (down 1.1 pp YoY)

## The ugly

- Consolidated operating loss of $303M in Q3 2026

## Open questions

- Impact of the initial option liability associated with the BlackRock JV on Q4 GAAP EPS
- Reconciliation of the ($0.01) difference in the 3Q26 GAAP to Adjusted EPS reconciliation

## Full release

### Humana (HUM) earnings release, November 6, 2026

Humana Inc (HUM) · Form 8-K, Item 2.02 · Filed 2026-11-06 · [SEC filing](https://www.sec.gov/Archives/edgar/data/49071/000004907126000064/)

FOR MORE INFORMATION CONTACT:

Mark Taylor

Humana Corporate Communications

(317) 753-0345 e-mail: MTaylor108@humana.com

Humana Reports Third Quarter 2026 Financial Results;

Raises

Full Year 2026 Adjusted

EPS Guidance

• Reports 3Q26 earnings per share (EPS) of $1.33 on a GAAP basis,

Adjusted loss per share of $0.70; reports year to date (YTD) 2026 EPS of $16.84 on a GAAP basis, $17.17 on an Adjusted basis

• 3Q26 Insurance segment GAAP benefit ratio of 93.7 percent, favorable to management's guidance of 'slightly above 94 percent'

• Raises

FY 2026 Adjusted EPS guidance to now be 'at least $9.50', up from the previous expectation of 'at least $9.00'; while revising GAAP EPS guidance to

'at least $15.09', up from the previous estimate of 'at least $6.52'

• Continued strategic expansion of the company's CenterWell and Medicaid footprints

◦ YTD growth of 146,800 patients, or 30 percent, in CenterWell Senior Primary Care

◦ Recently announced joint venture (JV) with BlackRock replaced the previous JVs with Welsh, Carson, Anderson & Stowe, enhancing balance sheet efficiency and providing greater financial flexibility at a reduced cost of capital, while also funding future growth

◦ YTD Medicaid membership growth of 103,600, or 7 percent, largely driven by the start of integrated Duals programs in Michigan, Illinois, and South Carolina

• Publishes prepared management remarks to Investor Relations page of www.humana.com ahead of this morning's 8:00 a.m. ET question and answer session to discuss its financial results for the quarter and expectations for future earnings

LOUISVILLE, KY (November 6, 2026) – Humana Inc. (NYSE: HUM) today reported consolidated pretax results and diluted earnings per share for the quarter ended September 30, 2026 (3Q26) versus the quarter ended September 30, 2025 (3Q25) and for the nine months ended September 30, 2026 (YTD 2026) versus the nine months ended September 30, 2025 (YTD 2025) as noted in the tables below.¹

Refer to the "Footnotes" section included herein for further explanation of disclosures for Adjusted (non-GAAP) financial measures, as well as reconciliations.

Please refer to the tables above, as well as the consolidated and segment highlight sections in the detailed earnings release for additional discussion of the factors impacting the year-over-year quarterly and YTD comparisons.

"Humana is delivering positive results for our members, our patients and their health," said Humana President and CEO Jim Rechtin. "We are also increasingly driving financial and operating performance toward being 'ahead' of our plan."

FY 2026 Earnings Guidance

Humana revises its GAAP EPS guidance for the year ending December 31, 2026 (FY 2026) to 'at least $15.09' from 'at least $6.52', while raising its Adjusted EPS guidance to

'at least $9.50' from the previous guidance of 'at least $9.00'. The FY 2026 Adjusted EPS guidance anticipates a year-over-year decline as a result of the Star Ratings headwind for Bonus Year (BY) 2026, net of mitigation.²

Refer to the "Footnotes" section included herein for further explanation of disclosures for Adjusted (non-GAAP) financial measures, as well as reconciliations.

Detailed Press Release

Humana’s full earnings press release, including the statistical pages, has been posted to the company’s Investor Relations site and may be accessed at https://humana.gcs-web.com/ or via a current report on Form 8-K filed by the company with the Securities and Exchange Commission this morning (available at www.sec.gov or on the company’s website).

Conference Call

Humana will host a live question-and-answer session for analysts at 8:00 a.m. Eastern time today to discuss its financial results for the quarter and the company’s expectations for future earnings. In advance of the question-and-answer session, Humana will post prepared management remarks to the Quarterly Results section of its Investor Relations page (https://humana.gcs-web.com/financial-information/quarterly-results).

A webcast of the 3Q26 earnings call may be accessed via Humana’s Investor Relations page at https://humana.gcs-web.com/.

If you anticipate asking a question during the question-and-answer session, please register in advance at this link - https://register-conf.media-server.com/register/BIe96a47a3d2724a5baa1fa1210aa58a13.

Upon registration, telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number and a unique registrant ID.

The company suggests participants listening via the web or the conference call sign in or dial in at least 15 minutes in advance of the call. For those unable to participate in the live event, the virtual presentation archive will be available in the Historical Webcasts and Presentations section of the Investor Relations page at https://humana.gcs-web.com/, approximately two hours following the live webcast.

Footnotes

The company has included financial measures throughout this earnings release that are not in accordance with GAAP. Management believes that these measures, when presented in conjunction with the corresponding GAAP measures, provide a comprehensive perspective to more accurately compare and analyze the company’s core operating performance over time. Consequently, management uses these non-GAAP (Adjusted) financial measures as consistent indicators of the company’s core business operations from period to period, as well as for planning and decision-making purposes and in determination of incentive compensation. Non-GAAP (Adjusted) financial measures should be considered in addition to, but not as a substitute for, or superior to, financial measures prepared in³ accordance with GAAP. The company’s non-GAAP measures are not intended to normalize earnings, eliminate volatility, or represent future performance. Non-GAAP measures are subject to inherent limitations and may differ from similarly titled measures used by other companies.... (truncated)sures in this earnings release are in accordance with GAAP unless otherwise indicated. Please refer to the footnotes for a detailed description of each item adjusted out of GAAP financial measures to arrive at non-GAAP (Adjusted) financial measures.

(a) For the periods covered in this earnings release, the following items are excluded from the non-GAAP financial measures described above, as applicable.

• Amortization associated with identifiable intangibles -

Since amortization varies based on the size and timing of acquisition activity, management believes the exclusion of this non-cash expense provides a more consistent and uniform indicator of performance from period to period. For all periods shown within this earnings release,

GAAP measures affected include consolidated pretax results, EPS, and Insurance and CenterWell segments' (loss) income from operations. The table below discloses respective period amortization expense for each segment:

• Put/call valuation adjustments associated with the company’s non-consolidating minority interest investments -

These non-cash amounts are the result of fair value measurements associated with the company's primary care strategic partnership and are unrelated to the company's core business performance. For all periods shown within this earnings release, GAAP measures affected include consolidated pretax results and EPS.

• Value creation initiatives -

These charges relate to the company's multi-year transformation program, as approved by management with defined scope and milestones. The intent of the program is to re-align the company’s cost structure, operating model, and technology footprint with evolving market conditions. These costs primarily include severance and associate exit costs, asset impairments, and external consulting expenses incurred to execute the program. These charges were recorded at the corporate level and not allocated to the segments. The company has consistently applied this adjustment across all periods. For all periods shown within this earnings release, GAAP measures affected include consolidated pretax results, EPS, and the consolidated operating cost ratio.

• Impairment charges

-

During 2026, the company recognized non-cash impairment charges related to investments for which the company held minority ownership interests that were deemed to be unrecoverable based on recent market activity. In YTD 2025, the company recognized non-cash impairment charges related to certain indefinite-lived intangible assets based on the company's estimate of future financial performance in certain state markets. These charges were recorded at the corporate level and not allocated to the segments. For 3Q26 and YTD 2026, GAAP measures affected include consolidated pretax results, EPS, and consolidated revenues. For YTD 2025, GAAP measures affected included consolidated pretax results, EPS, and the consolidated operating cost ratio.

• Impact of exit of employer group commercial medical products business -

These amounts relate to activity from the exit of the employer group commercial medical products business as announced by Humana on February 23, 2023. For 3Q25 and YTD 2025, GAAP measures affected include consolidated pretax results and EPS.

• Settlement of certain litigation expenses

- These charges relate to expenses the company recognized in connection with a discrete legal matter. The nature and magnitude of this settlement are not indicative of the company’s ongoing operations. For 3Q25 and YTD 2025, GAAP measures affected in this release include consolidated pretax results, EPS, the consolidated and Insurance segment operating costs ratios, and Insurance segment income from operations.

• Loss on sale of business -

This discrete disposition is not part of the company's ordinary course operations and the impacts recognized from the disposal do not reflect core operational performance. The loss primarily reflects the difference between the carrying value and proceeds at the time of sale. For 3Q25 and YTD 2025, GAAP measures affected in this release include consolidated pretax results and EPS.

• Cumulative net tax impact -

This adjustment represents the cumulative net impact of the corresponding tax benefit or expense at the applicable marginal rate related to the aforementioned items excluded from the applicable GAAP measures. For FY 2025, the tax adjustment reflects the impact of the loss on sale of business, which exceeded the book loss. The related tax benefit from the loss on sale of business is realizable via capital loss carryback. The tax impact of the aforementioned items differs from the statutory rates due to jurisdictional mix, limitations on deductibility, and other factors. The cumulative tax impact is not intended to represent a normalized effective tax rate or expected future tax outcomes. For all periods presented in this earnings release,

EPS is the sole GAAP measure affected.⁴

In addition to the reconciliations shown on page 2 of this release, the following are reconciliations of GAAP to Adjusted (non-GAAP) measures described above and disclosed within this earnings release:

Revenues

Operating cost ratio

Insurance Segment - (Loss) income from operations

(b)

3Q26 GAAP to Adjusted (non-GAAP) EPS reconciliation will not foot due to a ($0.01) impact resulting from the use of common shares to calculate the Adjusted loss per share versus the use of diluted weighted-average shares in the calculation of GAAP EPS.

(c) Includes the noncash reversal of the net put liability of approximately $1.2 billion reflected in the company's September 30, 2026 balance sheet; the put was associated with CenterWell Senior Primary Care's previous joint ventures with Welsh, Carson, Anderson & Stowe.... (truncated)e. The company does not expect changes to its FY 2026 Adjusted (non-GAAP) EPS guidance. The company does expect potential changes to its FY 2026 GAAP EPS guidance due to its ongoing value creation and other strategic initiatives.⁵ e) Reflects the new initial option liability associated with the company's recently announced non-consolidating strategic joint venture with HPS Investment Partners, a subsidiary of BlackRock and CenterWell Senior Primary Care; this noncash impact is expected to be recorded in the fourth quarter of 2026. Management excludes the initial recognition because it results from the transaction’s ownership and option structure, and it is not considered in management’s evaluation of core operating results.

Cautionary Statement

This news release includes forward-looking statements regarding Humana within the meaning of the Private Securities Litigation Reform Act of 1995. When used in investor presentations, press releases, Securities and Exchange Commission (SEC) filings, and in oral statements made by or with the approval of one of Humana’s executive officers, the words or phrases like “expects,” “believes,” “anticipates,” “assumes,” “intends,” “likely will result,” “estimates,” “projects” or variations of such words and similar expressions are intended to identify such forward-looking statements.

These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and assumptions, including, among other things, information set forth in the “Risk Factors” section of the company’s SEC filings, a summary of which includes but is not limited to the following:

• If Humana does not design and price its products properly and competitively, if the premiums Humana receives are insufficient to cover the cost of healthcare services delivered to its members, if the company is unable to implement clinical initiatives to provide a better healthcare experience for its members, lower costs and appropriately document the risk profile of its members, or if its estimates of benefits expense are inadequate, Humana’s profitability could be materially adversely affected. Humana estimates the costs of its benefit expense payments, and designs and prices its products accordingly, using actuarial methods and assumptions based upon, among other relevant factors, claim payment patterns, medical cost inflation, and historical developments such as claim inventory levels and claim receipt patterns. The company continually reviews estimates of future payments relating to benefit expenses for services incurred in the current and prior periods and makes necessary adjustments to its reserves, including premium deficiency reserves, where appropriate. These estimates involve extensive judgment, and have considerable inherent variability because they are extremely sensitive to changes in claim payment patterns and medical cost trends. Accordingly, Humana's reserves may be insufficient.

• If Humana fails to effectively implement its operational and strategic initiatives, including its Medicare initiatives, which are of particular importance given the concentration of the company's revenues in these products, state-based contract strategy, the growth of its CenterWell business, and its integrated care delivery model, the company’s business may be materially adversely affected.

• The number of Humana’s Medicare Advantage plans rated 4-star or higher significantly declined in 2025. Humana filed a lawsuit seeking to set aside and vacate the 2025 Star Ratings of its Medicare Advantage plans, and on October 14, 2025, the Court issued a decision rejecting Humana's challenge. Although the company has appealed that decision, there can be no assurances that it will ultimately prevail in the lawsuit. If the company is not successful, the decline in Star Ratings will negatively impact its 2026 quality bonus payments from CMS and may also significantly adversely affect the company’s revenues, operating results, and cash flows. In addition, there can be no assurances the company will be successful in maintaining or improving its Star Ratings in future years.

• If Humana, or the third-party service providers on which it relies, fails to properly maintain the integrity of its data, to strategically maintain existing or implement new information systems (including systems powered by or incorporating artificial intelligence (AI) or machine learning (ML)), or to protect Humana’s proprietary rights to its systems, or to defend against cyber-security attacks, contain such attacks when they occur, or prevent other privacy or data security incidents that result in security breaches that disrupt the company's operations or in the unintentional dissemination of sensitive personal information or proprietary or confidential information, the company’s business may be materially adversely affected.

• Humana is involved in various legal actions, or disputes that could lead to legal actions (such as, among other things, provider contract disputes and qui tam litigation brought by individuals on behalf of the government), governmental and internal investigations, and routine internal review of business processes any of which, if resolved unfavorably to the company, could result in substantial monetary damages or⁶ changes in its business practices. Increased litigation and negative publicity could also increase the company’s cost of doing business.

• ... (truncated)e governmental programs in which Humana participates. Changes to the risk-adjustment model utilized by CMS to adjust premiums paid to Medicare Advantage plans or retrospective recovery by CMS of previously paid premiums as a result of the final rule related to the risk adjustment data validation audit methodology published by CMS on January 30, 2023 (Final RADV Rule), which Humana believes fails to address adequately the statutory requirement of actuarial equivalence and violates the Administrative Procedure Act due to its failure to include a "Fee for Service Adjuster" could have a material adverse effect on the company's operating results, financial position and cash flows.

• Humana's business activities are subject to substantial government regulation. New laws or regulations, or legislative, judicial, or regulatory changes in existing laws or regulations or their manner of application could increase the company's cost of doing business and have a material adverse effect on Humana’s results of operations (including restricting revenue, enrollment and premium growth in certain products and market segments, restricting the company’s ability to expand into new markets, increasing the company’s medical and operating costs by, among other things, requiring a minimum benefit ratio on insured products, lowering the company’s Medicare payment rates and increasing the company’s expenses associated with a non-deductible health insurance industry fee and other assessments); the company’s financial position (including the company’s ability to maintain the value of its goodwill); and the company’s cash flows.

• Humana’s failure to manage acquisitions, divestitures and other significant transactions successfully may have a material adverse effect on the company’s results of operations, financial position, and cash flows.

• If Humana fails to develop and maintain satisfactory relationships with the providers of care to its members, the company’s business may be adversely affected.

• Humana faces significant competition in attracting and retaining talented employees. Further, managing succession for, and retention of, key executives is critical to the Company’s success, and its failure to do so could adversely affect the Company’s businesses, operating results and/or future performance.

• Humana’s pharmacy business is highly competitive and subjects it to regulations and supply chain risks in addition to those the company faces with its core health benefits businesses.

• Changes in the prescription drug industry pricing benchmarks may adversely affect Humana’s financial performance.

• Humana’s ability to obtain funds from certain of its licensed subsidiaries is restricted by state insurance regulations.

• Downgrades in Humana’s debt ratings, should they occur, may adversely affect its business, results of operations, and financial condition.

• Volatility or disruption in the securities and credit markets may significantly and adversely affect the value of our investment portfolio and the investment income that we derive from this portfolio.

In making forward-looking statements, Humana is not undertaking to address or update them in future filings or communications regarding its business or results. In light of these risks, uncertainties, and assumptions, the forward-looking events discussed herein may or may not occur. There also may be other risks that the company is unable to predict at this time. Any of these risks and uncertainties may cause actual results to differ materially from the results discussed in the forward-looking statements.

Humana advises investors to read the following documents as filed by the company with the SEC for further discussion both of the risks it faces and its historical performance:

• Form 10-K for the year ended December 31, 2025;

• Form 10-Q for the quarters ended March 31, 2026 and June 30, 2026; and⁷

• Form 8-Ks filed during 2026.

About Humana

Humana (NYSE: HUM) is a leading U.S. healthcare company. Through our Humana insurance services and our CenterWell health care services, we make it easier for the millions of people we serve to achieve their best health – delivering the care and service they need, when they need it. These efforts are leading to a better quality of life for people with Medicare and Medicaid, families, individuals, military service personnel, and communities at large. Learn more about what we offer at Humana.com and at CenterWell.com.⁸

#### Financial statements

##### Income Statement (YTD 2026 (a) — Humana Consolidated Highlights ($ in millions, except per share amounts))

| | 3Q26 (a) | 3Q25 (a) | YTD 2026 (a) | YTD 2025 (a) |
|---|---:|---:|---:|---:|
| Revenues | 41,155 | 32,649 | 121,670 | 97,149 |
| Revenues - Adjusted (non-GAAP) | 41,158 | 32,649 | 121,694 | 97,149 |
| Pretax results | 216 | 134 | 2,763 | 2,566 |
| Pretax results - Adjusted (non-GAAP) | -104 | 527 | 2,814 | 3,437 |
| EPS | 1.33 | 1.62 | 16.84 | 16.43 |
| Adjusted (loss) earnings per share - (non-GAAP) | -0.7 | 3.24 | 17.17 | 21.1 |
| Benefit ratio | 93.9 | 91.1 | 91.5 | 89.3 |
| Operating cost ratio | 11.3 | 12.6 | 10.4 | 11.4 |
| Operating cost ratio - Adjusted (non-GAAP) | 11.2 | 11.8 | 10.3 | 11.1 |
| Operating cash flows |  |  | 5,383 | 2,573 |
| Parent company cash and short-term investments |  |  | 528 | 1,940 |
| Debt-to-total capitalization |  |  | 40.9 | 40.3 |
| Days in Claims Payable (DCP) | 33.2 | 33.2 |  |  |

##### Income Statement (YTD 2026 (a) (in millions))

| | 3Q26 (a) | 3Q25 (a) | YTD 2026 (a) | YTD 2025 (a) |
|---|---:|---:|---:|---:|
| Revenues | 39,083 | 31,189 | 116,282 | 93,220 |
| Benefit ratio | 93.7 | 91.1 | 91.4 | 89.5 |
| Operating cost ratio | 7.7 | 9.1 | 7.4 | 8.5 |
| Operating cost ratio - Adjusted (non-GAAP) | 7.7 | 9 | 7.4 | 8.5 |
| (Loss) income from operations | -303 | 251 | 1,952 | 2,591 |
| (Loss) income from operations - Adjusted (non-GAAP) | -299 | 270 | 1,964 | 2,619 |

##### Income Statement (Humana Inc. FY 2026 Guidance - As of November 6, 2026)

| | Humana Inc. FY 2026 Guidance - As of November 6, 2026 – no changes from initial FY 2026 guidance provided as of February 11, 2026, with the exception of GAAP and Adjusted EPS – Guidance as of July 29, 2026 – Diluted earnings per common share (EPS) – GAAP: 'at least $6.52' – Non-GAAP: 'at least $9.00' – Total Revenues – At least $160 billion – At least $155 billion – At least $25 billion – Change in year-end medical membership from prior year-end – growth of approximately 25 percent – growth of approximately 150,000 – growth of approximately 1,000,000 – growth of 25,000 to 100,000 |
|---|---:|
| Benefit Ratio Insurance segment | GAAP: 92.75% +/- 25 bps |
| **Consolidated Operating Cost Ratio** | |
| Operating Cost Ratio Consolidated | GAAP: 10.0% +/- 25 bps |
| **Segment Results** | |
| Insurance segment income from operations | GAAP: approximately breakeven |
| CenterWell segment income from operations | GAAP: $1.3 billion to $1.8 billion Non-GAAP: $1.5 billion to $2.0 billion |
| Effective Tax Rate | GAAP: approximately 25.5% |
| Weighted Avg. Share Count for Diluted EPS | approximately 121 million |
| Cash flows from operations | GAAP: $2.5 billion to $2.9 billion |
| Capital expenditures | approximately $650 million |

##### Income Statement (For the three months ended September 30, — Dollars in millions, except per common share results)

| | For the three months ended September 30, – 2026 | For the three months ended September 30, – 2025 | For the nine months ended September 30, – 2026 | For the nine months ended September 30, – 2025 |
|---|---:|---:|---:|---:|
| **Revenues:** | | | | |
| Premiums | 38,701 | 30,711 | 115,244 | 91,941 |
| Services | 2,125 | 1,600 | 5,582 | 4,334 |
| Net investment income | 329 | 338 | 844 | 874 |
| Total revenues | 41,155 | 32,649 | 121,670 | 97,149 |
| **Operating expenses:** | | | | |
| Benefits | 36,324 | 27,991 | 105,401 | 82,091 |
| Operating costs | 4,598 | 4,085 | 12,600 | 11,012 |
| Depreciation and amortization | 158 | 173 | 480 | 534 |
| Total operating expenses | 41,080 | 32,249 | 118,481 | 93,637 |
| Income from operations | 75 | 400 | 3,189 | 3,512 |
| Loss on sale of business |  | 63 |  | 63 |
| Interest expense | 217 | 168 | 607 | 485 |
| Other (income) expense, net | -358 | 35 | -181 | 398 |
| Income before income taxes and equity in net losses | 216 | 134 | 2,763 | 2,566 |
| Provision (benefit) for income taxes | 40 | -86 | 673 | 499 |
| Equity in net losses (A) | -15 | -26 | -52 | -88 |
| Net income | 161 | 194 | 2,038 | 1,979 |
| Net loss attributable to noncontrolling interests | 1 | 1 | 4 | 5 |
| Net income attributable to Humana | 162 | 195 | 2,042 | 1,984 |
| Basic earnings per common share | 1.35 | 1.62 | 16.99 | 16.47 |
| Diluted earnings per common share | 1.33 | 1.62 | 16.84 | 16.43 |
| Shares used in computing basic earnings per common share (000’s) | 120,094 | 120,273 | 120,164 | 120,492 |
| Shares used in computing diluted earnings per common share (000’s) | 121,828 | 120,745 | 121,205 | 120,778 |

##### Income Statement (Eliminations/ Corporate — In millions)

| | Insurance | CenterWell | Eliminations/ Corporate | Consolidated |
|---|---:|---:|---:|---:|
| **Revenues—external customers premiums:** | | | | |
| Individual Medicare Advantage | 28,619 |  |  | 28,619 |
| Group Medicare Advantage | 2,793 |  |  | 2,793 |
| Medicare stand-alone PDP | 3,014 |  |  | 3,014 |
| Total Medicare | 34,426 |  |  | 34,426 |
| State-based contracts and other | 3,641 |  |  | 3,641 |
| Specialty benefits | 271 |  |  | 271 |
| Medicare Supplement | 363 |  |  | 363 |
| Total premiums | 38,701 |  |  | 38,701 |
| **Services revenue:** | | | | |
| Home solutions |  | 359 |  | 359 |
| Primary care |  | 948 |  | 948 |
| Pharmacy solutions |  | 564 |  | 564 |

##### Income Statement (Eliminations/ Corporate — In millions)

| | Insurance | CenterWell | Eliminations/ Corporate | Consolidated |
|---|---:|---:|---:|---:|
| **Revenues—external customers premiums:** | | | | |
| Individual Medicare Advantage | 22,456 |  |  | 22,456 |
| Group Medicare Advantage | 2,240 |  |  | 2,240 |
| Medicare stand-alone PDP | 1,755 |  |  | 1,755 |
| Total Medicare | 26,451 |  |  | 26,451 |
| State-based contracts and other | 3,729 |  |  | 3,729 |
| Specialty benefits | 248 |  |  | 248 |
| Medicare Supplement | 283 |  |  | 283 |
| Total premiums | 30,711 |  |  | 30,711 |
| **Services revenue:** | | | | |
| Home solutions |  | 354 |  | 354 |
| Primary care |  | 627 |  | 627 |
| Pharmacy solutions |  | 352 |  | 352 |
| Military services and other | 267 |  |  | 267 |
| Total services revenue | 267 | 1,333 |  | 1,600 |
| Total revenues—external customers | 30,978 | 1,333 |  | 32,311 |
| Intersegment revenues | 1 | 4,546 | -4,547 |  |
| Net investment income | 210 |  | 128 | 338 |
| Total revenues | 31,189 | 5,879 | -4,419 | 32,649 |
| **Operating expenses:** | | | | |
| Benefits | 27,982 |  | 9 | 27,991 |
| Operating costs | 2,808 | 5,521 | -4,244 | 4,085 |
| Depreciation and amortization | 148 | 53 | -28 | 173 |
| Total operating expenses | 30,938 | 5,574 | -4,263 | 32,249 |
| Income (loss) from operations | 251 | 305 | -156 | 400 |
| Benefit ratio | 91.1 |  |  | 91.1 |
| Operating cost ratio | 9.1 | 93.9 |  | 12.6 |

##### Income Statement (Eliminations/ Corporate — In millions)

| | Insurance | CenterWell | Eliminations/ Corporate | Consolidated |
|---|---:|---:|---:|---:|
| **Revenues—external customers premiums:** | | | | |
| Individual Medicare Advantage | 85,746 |  |  | 85,746 |
| Group Medicare Advantage | 8,555 |  |  | 8,555 |
| Medicare stand-alone PDP | 8,626 |  |  | 8,626 |
| Total Medicare | 102,927 |  |  | 102,927 |
| State-based contracts and other | 10,474 |  |  | 10,474 |
| Specialty benefits | 807 |  |  | 807 |
| Medicare Supplement | 1,036 |  |  | 1,036 |
| Total premiums | 115,244 |  |  | 115,244 |
| **Services revenue:** | | | | |
| Home solutions |  | 1,062 |  | 1,062 |
| Primary care |  | 2,575 |  | 2,575 |
| Pharmacy solutions |  | 1,243 |  | 1,243 |
| Military services and other | 700 |  | 2 | 702 |
| Total services revenue | 700 | 4,880 | 2 | 5,582 |
| Total revenues—external customers | 115,944 | 4,880 | 2 | 120,826 |
| Intersegment revenues | 4 | 15,167 | -15,171 |  |
| Net investment income | 334 |  | 510 | 844 |
| Total revenues | 116,282 | 20,047 | -14,659 | 121,670 |
| **Operating expenses:** | | | | |
| Benefits | 105,371 |  | 30 | 105,401 |
| Operating costs | 8,541 | 18,904 | -14,845 | 12,600 |
| Depreciation and amortization | 418 | 145 | -83 | 480 |
| Total operating expenses | 114,330 | 19,049 | -14,898 | 118,481 |
| Income from operations | 1,952 | 998 | 239 | 3,189 |
| Benefit ratio | 91.4 |  |  | 91.5 |
| Operating cost ratio | 7.4 | 94.3 |  | 10.4 |

##### Income Statement (Eliminations/ Corporate — In millions)

| | Insurance | CenterWell | Eliminations/ Corporate | Consolidated |
|---|---:|---:|---:|---:|
| **Revenues—external customers premiums:** | | | | |
| Individual Medicare Advantage | 67,901 |  |  | 67,901 |
| Group Medicare Advantage | 6,822 |  |  | 6,822 |
| Medicare stand-alone PDP | 4,924 |  |  | 4,924 |
| Total Medicare | 79,647 |  |  | 79,647 |
| State-based contracts and other | 10,757 |  |  | 10,757 |
| Specialty benefits | 738 |  |  | 738 |
| Medicare Supplement | 799 |  |  | 799 |
| Total premiums | 91,941 |  |  | 91,941 |
| **Services revenue:** | | | | |
| Home solutions |  | 1,049 |  | 1,049 |
| Primary care |  | 1,609 |  | 1,609 |
| Pharmacy solutions |  | 951 |  | 951 |
| Military services and other | 725 |  |  | 725 |
| Total services revenue | 725 | 3,609 |  | 4,334 |
| Total revenues—external customers | 92,666 | 3,609 |  | 96,275 |
| Intersegment revenues | 3 | 12,902 | -12,905 |  |
| Net investment income | 551 |  | 323 | 874 |

##### Balance Sheet (September 30, — Dollars in millions, except share amounts)

| | September 30, – 2026 | December 31, – 2025 |
|---|---:|---:|
| **Current assets:** | | |
| Cash and cash equivalents | 6,935 | 4,200 |
| Investment securities | 18,174 | 15,703 |
| Receivables, net | 2,865 | 3,270 |
| Other current assets | 11,635 | 9,560 |
| Total current assets | 39,609 | 32,733 |
| Property and equipment, net | 2,070 | 2,231 |
| Long-term investment securities | 606 | 493 |
| Equity method investments | 621 | 638 |
| Goodwill | 10,547 | 9,686 |
| Other long-term assets | 3,832 | 3,128 |
| Total assets | 57,285 | 48,909 |
| **Current liabilities:** | | |
| Benefits payable | 13,127 | 9,967 |
| Trade accounts payable and accrued expenses | 9,390 | 5,717 |
| Book overdraft | 316 | 306 |
| Unearned revenues | 270 | 356 |
| Short-term debt | 949 |  |
| Total current liabilities | 24,052 | 16,346 |
| Long-term debt | 11,555 | 12,369 |
| Other long-term liabilities | 2,790 | 2,457 |
| Total liabilities | 38,397 | 31,172 |
| **Stockholders’ equity:** | | |
| Common stock, $0.16 2/3 par; 300,000,000 shares authorized; 198,719,832 issued at September 30, 2026 | 33 | 33 |
| Capital in excess of par value | 3,774 | 3,600 |
| Retained earnings | 30,796 | 29,075 |
| Accumulated other comprehensive loss | -1,270 | -633 |
| Treasury stock, at cost, 78,616,582 shares at September 30, 2026 | -14,508 | -14,418 |
| Total stockholders’ equity | 18,825 | 17,657 |
| Noncontrolling interests | 63 | 80 |
| Total equity | 18,888 | 17,737 |
| Total liabilities and equity | 57,285 | 48,909 |
| Debt-to-total capitalization ratio | 40.9 | 41.1 |

##### Cash Flow (For the nine months ended September 30, — Dollars in millions)

| | For the nine months ended September 30, – 2026 | For the nine months ended September 30, – 2025 |
|---|---:|---:|
| **Cash flows from operating activities** | | |
| Net income | 2,038 | 1,979 |
| **Adjustments to reconcile net income to net cash provided by operating activities:** | | |
| Loss on sale of business |  | 63 |
| Losses (gains) on investment securities, net | 30 | -66 |
| Equity in net losses | 52 | 88 |
| Stock-based compensation | 183 | 193 |
| Depreciation | 540 | 587 |
| Amortization | 29 | 43 |
| Impairment of property and equipment | 34 | 14 |
| Impairment of indefinite-lived intangible assets |  | 32 |
| **Changes in operating assets and liabilities, net of effect of businesses acquired and disposed:** | | |
| Receivables | 439 | 16 |
| Other assets | -1,274 | -1,374 |
| Benefits payable | 3,160 | -351 |
| Other liabilities | 221 | 1,317 |
| Unearned revenues | -86 | 5 |
| Other, net | 17 | 27 |
| Net cash provided by operating activities | 5,383 | 2,573 |
| **Cash flows from investing activities** | | |
| Proceeds from sale of business, net | 40 | 115 |
| Acquisitions, net of cash acquired | -1,007 | -5 |
| Purchases of property and equipment, net | -390 | -344 |
| Purchases of investment securities | -7,070 | -5,198 |
| Proceeds from maturities of investment securities | 2,296 | 2,148 |
| Proceeds from sales of investment securities | 1,415 | 5,066 |
| Changes in securities lending collateral receivable | -179 | -141 |
| Net cash (used in) provided by investing activities | -4,895 | 1,641 |
| **Cash flows from financing activities** | | |
| Receipts (payments) from contract deposits, net | 1,787 | -1,164 |
| Proceeds from issuance of notes, net | 990 | 1,481 |
| Repayments of notes | -281 | -771 |
| Repayments of commercial paper, net | -30 | -5 |
| FHLB advances | 100 |  |

##### Income Statement (in millions)

| | 3Q26 | 3Q25 | YTD 2026 | YTD 2025 |
|---|---:|---:|---:|---:|
| Revenues | 7,157 | 5,879 | 20,047 | 16,511 |
| Operating cost ratio | 95.9 | 93.9 | 94.3 | 92.7 |
| Income from operations | 243 | 305 | 998 | 1,041 |
| Income from operations - Adjusted (non-GAAP) (f) | 291 | 358 | 1,143 | 1,213 |
